TABLE 1

MTX plasma AUCs of female mice after intravenous (0–120 min) and oral (0–6 h) administration of 50 mg/kg MTX

MTX plasma AUCs are presented as minutes per microgram per milliliter, and oral availabilities (F) are given as a percentage of AUC_i.v. (means ± S.D.; n = 2–14). Intravenous (0–120 min) data are from Vlaming et al. (2009b).

	Strain
	Wild-Type	Abcc2(−/−)	Abcc3(−/−)	Abcg2(−/−)	Abcc2;Abcc3(−/−)	Abcc2;Abcg2(−/−)	Abcc3;Abcg2(−/−)	Abcc2;Abcc3;Abcg2(−/−)
AUC_{oral 0–6 h} (min · μg/ml)	62 ± 13	85 ± 14	48 ± 13	107 ± 14^*	43 ± 9	184 ± 31^**	60 ± 11	53 ± 5
Fold difference^{^a}	1.0	1.4	0.8	1.7	0.7	3.0	1.0	0.9
AUC_{i.v. 0–120 min} (min · μg/ml)	444 ± 44	870 ± 103^***	368 ± 34	692 ± 56^*	435 ± 47	1446 ± 229^**	451 ± 26	603 ± 56^*
Fold difference^{^a}	1.0	2.0	0.8	1.6	1.0	3.3	1.0	1.4
F (oral/intravenous) (%)	14.0 ± 3.2	9.8 ± 2.0	13.1 ± 3.7	15.6 ± 2.4	9.8 ± 2.4	12.8 ± 2.9	13.4 ± 2.6	8.9 ± 1.2^*

↵* P < 0.05, compared with wild-type mice. Student's t test was used for statistical analysis.
↵** P < 0.01.
↵*** P < 0.001.
↵a Fold difference represents fold difference compared with wild-type mice with the same route of administration.